COMPANY DESCRIPTION
Flagship Labs 68 (FL68) is a privately held, well-funded, early-stage biotechnology company that is developing a novel cell therapy platform, which leverages unique cell types and behaviors to perform entirely new therapeutic functions. Fully realized, the FL68 platform technology will tackle a massive spectrum of diseases, drastically extending the reach of cell therapy for human health. We are a dynamic, entrepreneurial, and innovation-driven group seeking collaborative and dedicated people to join our team.
THE ROLE
FL68 is seeking an innovative and highly motivated Senior Research Associate with experience in culturing of mammalian cells in bioreactor systems. This candidate will play a pivotal role in the company’s efforts to optimize platform capabilities and transition findings into early pre-clinical studies. The ideal candidate will thrive in a collaborative, fast-paced entrepreneurial environment and possess excellent communication skills.
KEY RESPONSIBILITIES
- Develop and implement protocols for the efficient use of bioreactors in stem cell culture and differentiations to enhance performance and scalability.
- Support efforts in small-scale bioreactor process optimization and support the transition of processes to larger scale systems.
- Perform cell-based and molecular assays (e.g. ELISAs, qRT-PCR, metabolic analytics) to evaluate process outcomes.
- Collaborate effectively with multidisciplinary teams, including research and development and in-vivo teams, providing insights and updates on project progress and outcomes.
- Conduct data and statistical analysis for process optimization and reporting.
- Maintain a detailed and up-to-date electronic lab notebook and write high quality experimental protocols.
- Present experimental plans and results to the scientific team and management.
- Availability to work some weekends.
PROFESSIONAL EXPERIENCE & QUALIFICATIONS
- MS in engineering, life sciences, biotechnology, biology, or related field with 0-2 years of relevant bioprocessing experience in industry.
- BA in engineering, life sciences, biotechnology, biology, or related field with 2-4 years of relevant bioprocessing experience in industry.
- Demonstrated experience in bioreactor systems. Experience with continuous perfusion processes for mammalian cell culture is a plus.
- Experience with coding for automated systems is a plus.
- Experience with induced pluripotent stem cells (iPSC) is a plus but not required.
- Must possess a high degree of flexibility and adaptability to evolving job requirements and priorities.
ABOUT FLAGSHIP PIONEERING
Flagship Pioneering invents and builds platform companies, each with the potential for multiple products that transform human health, sustainability and beyond. Since its launch in 2000, Flagship has originated more than 100 companies. Many of these companies have addressed humanity’s most urgent challenges: vaccinating billions of people against COVID-19, curing intractable diseases, improving human health, preempting illness, and feeding the world by improving the resiliency and sustainability of agriculture.
Flagship has been recognized twice on FORTUNE’s “Change the World” list, an annual ranking of companies that have made a positive social and environmental impact through activities that are part of their core business strategies and has been twice named to Fast Company’s annual list of the World’s Most Innovative Companies. Learn more about Flagship at www.flagshippioneering.com.
At Flagship, we accept impossible missions to enable bigger leaps. Our core values guide us through uncertainty and toward lasting impact.
We are an equal opportunity employer. All qualified applicants will be considered for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, protected veteran status, or any other characteristic protected by law.
We recognize that great candidates often bring unique strengths without fulfilling every qualification. If you have some of the experience listed above but not all, please apply anyway. We are dedicated to building diverse and inclusive teams and look forward to learning more about your background and interest in Flagship.
Recruitment & Staffing Agencies: Flagship Pioneering and its affiliated Flagship Lab companies (collectively, “FSP”) do not accept unsolicited resumes from any source other than candidates. The submission of unsolicited resumes by recruitment or staffing agencies to FSP or its employees is strictly prohibited unless contacted directly by Flagship Pioneering’s internal Talent Acquisition team. Any resume submitted by an agency in the absence of a signed agreement will automatically become the property of FSP, and FSP will not owe any referral or other fees with respect thereto.
#LI-TD1
The salary range for this role is $81,000 - $107,250. Compensation for the role will depend on a number of factors, including a candidate’s qualifications, skills, competencies, and experience. FL68 currently offers healthcare coverage, annual incentive program, retirement benefits and a broad range of other benefits. Compensation and benefits information is based on FL68’s good faith estimate as of the date of publication and may be modified in the future.
Top Skills
What We Do
Flagship Pioneering conceives, creates, resources, and develops first-in-category life sciences companies to transform human health and sustainability.
Since its launch in 2000, the firm has applied a unique, hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $30 billion in aggregate value. To date, Flagship is backed by >$3 billion of aggregate capital commitments, of which over $1.5 billion has been deployed toward the founding and growth of its pioneering companies alongside >$10 billion of follow-on investments from other institutions.
The current Flagship ecosystem includes Denali Therapeutics (NASDAQ: DNLI), Evelo Biosciences (NASDAQ: EVLO), Moderna Therapeutics (NASDAQ: MRNA), Rubius Therapeutics (NASDAQ: RUBY), Seres Therapeutics (NASDAQ: MCRB), and Syros Pharmaceuticals (NASDAQ: SYRS).
